Is WST a good stock to buy right now?

Based on our 6-factor quantitative model, WEST PHARMACEUTICAL SERVICES INC (WST) receives a "Hold" rating with a composite score of 44.9/100. It is ranked #734 out of 4,446 stocks. Key factor scores: Quality 50/100, Value 53/100, Momentum 42/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for WST?

WEST PHARMACEUTICAL SERVICES INC (WST) has a "Hold" rating and 3-star score. The composite score of 44.9 ranks it #734 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is WST in?

WEST PHARMACEUTICAL SERVICES INC operates in the Healthcare sector (Medical Equipment industry) with a market cap of $18.22 billion. It is classified as a large-cap stock.

Does WST pay a dividend?

Yes, WST pays a dividend with a current yield of 0.32%. For every $1,000 invested, you would receive approximately $3.20 in annual dividend income.

What is WST's P/E ratio?

WST has a trailing P/E ratio of 37.57x. The Healthcare sector average is 23.6x. This above-average P/E reflects growth expectations or premium valuation.

How profitable is WST?

WST's quality factor score is 50/100. Gross margin: 35.2%. ROE: 15.7% vs sector average -43.5%. Margins are moderate to low, reflecting competitive market dynamics.

How is WST valued compared to peers?

WST's value factor score is 53/100 (higher = cheaper). Key multiples: P/E 37.6x, EV/EBITDA 32.0x. Valuation is roughly in line with peers.

What is WST's debt level?

WST's debt-to-equity ratio is 6%. Sector average: 32%. Low leverage suggests conservative financial management.

WST has a beta of 0.73, meaning it is less volatile than the market. Stability score: 67/100.

Does WST have high short interest?

WST's short interest factor score is 22/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

WST Stock Analysis: Hold (Score 44.9/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
WST	-0.77%	+0.69%	+9.72%	-6.76%	+25.91%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	-0.70%	-2.92%	+9.38%	-6.40%	-3.61%	-	-	-
Alpha vs Sector	+0.58%	+0.35%	+13.53%	-1.92%	+16.71%	-	-	-

Metric	WST	Benchmark
P/E Ratio	37.6x	+59%
EV/EBITDA	32.0x	+406%
Price / Book	5.9x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS
WST WEST PHARMACEUTICAL SERVICES INC	45	50	53	42	37.6x	15.7%	35.2%	16.4%	14.6%	6.0x	$18.2B

Key Ratio	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Gross Margin %	0.4%	0.4%	0.3%	0.4%	0.4%	0.4%	0.4%	0.3%	0.3%	0.3%	0.3%
Operating Margin %	0.2%	0.2%	0.2%	0.2%	0.3%	0.3%	0.2%	0.2%	0.1%	0.1%	0.1%
EBITDA Margin %	0.2%	0.2%	0.2%	0.2%	0.3%	0.3%	0.2%	0.2%	0.2%	0.2%	0.2%
Net Margin %	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.1%	0.1%	0.1%	0.1%
FCF Margin %	-0.8%	-	-	-	-	-	13.9%	13.1%	10.7%	8.3%	3.3%
ROE %	0.2%	0.2%	0.2%	0.2%	0.2%	0.3%	0.2%	0.2%	0.1%	0.1%	0.1%
ROA %	0.1%	0.1%	0.1%	0.2%	0.2%	0.2%	0.1%	0.1%	0.1%	0.1%	0.1%
ROIC %	0.1%	13.7%	15.6%	17.3%	20.0%	23.0%	21.5%	16.8%	15.1%	14.4%	13.6%

Key Ratio

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

Gross Margin %

0.4%

0.3%

0.4%

0.3%

Operating Margin %

0.2%

0.3%

0.2%

0.1%

EBITDA Margin %

0.2%

0.3%

0.2%

Net Margin %

0.2%

0.1%

FCF Margin %

-0.8%

13.9%

13.1%

10.7%

8.3%

3.3%

ROE %

0.2%

0.3%

0.2%

0.1%

ROA %

0.1%

0.2%

0.1%

ROIC %

0.1%

13.7%

15.6%

17.3%

20.0%

23.0%

21.5%

16.8%

15.1%

14.4%

13.6%

Line Item	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
	$3.0B	$3.1B	$2.9B	$2.9B	$2.9B	$2.8B	$2.1B	$1.8B	$1.7B	$1.6B	$1.5B	$1.4B
	—	$2.0B	$1.9B	$1.8B	$1.8B	$1.7B	—	—	—	—	—	—
	$1.1B	$1.1B	$999M	$1.1B	$1.1B	$1.2B	$768M	$606M	$545M	$513M	$501M	$456M
Gross Margin	35.2%	35.9%	34.5%	38.3%	39.4%	41.5%	35.8%	32.9%	31.8%	32.1%	33.2%	32.6%
	—	$394M	$339M	$353M	$317M	$363M	—	—	—	—	—	—
Research & Development	—	$74M	$69M	$68M	$59M	$53M	$47M	$39M	$40M	$39M	$37M	$34M
Depreciation	—	—	—	—	—	—	$109M	$103M	$104M	$97M	$91M	$90M
Total Operating Expenses	—	$519M	$429M	$453M	$402M	$424M	—	—	—	—	—	—
	$590M	$585M	$570M	$676M	$734M	$752M	$407M	$297M	$240M	$226M	$197M	$129M
EBIT	$590M	$585M	$570M	$676M	$734M	$752M	$407M	$297M	$240M	$226M	$197M	$129M
EBITDA	$590M	$585M	$570M	$676M	$734M	$752M	$517M	$400M	$351M	$326M	$288M	$219M
Operating Margin	19.5%	19.0%	19.7%	22.9%	25.4%	26.6%	18.9%	16.1%	14.0%	14.1%	12.9%	9.2%
EBITDA Margin	19.6%	19.0%	19.7%	22.9%	25.4%	26.6%	24.1%	21.7%	20.5%	20.4%	19.1%	15.6%
	—	—	—	$9M	$8M	$8M	$8M	$9M	$8M	$8M	$8M	$14M
	—	$601M	$586M	$698M	$680M	$749M	—	—	—	—	—	—
Income Tax Expense	—	$122M	$108M	$122M	$115M	$107M	$73M	$59M	$41M	$81M	$54M	$26M
	$498M	$494M	$493M	$593M	$586M	$662M	$346M	$242M	$207M	$151M	$144M	$96M
Net Margin	16.4%	16.1%	17.0%	20.1%	20.3%	23.4%	16.1%	13.1%	12.0%	9.4%	9.5%	6.8%
	$6.83	$6.83	$6.75	$7.98	$7.87	$8.89	$4.68	$3.27	$2.80	$2.04	$1.96	$1.33
Diluted EPS	$6.83	$6.79	$6.69	$7.88	$7.73	$8.67	$4.68	$3.27	$2.80	$2.04	$1.96	$1.33
Weighted Avg Basic	—	72M	73M	74M	74M	74M	—	—	—	—	—	—
Weighted Avg Diluted	—	73M	74M	75M	76M	76M	—	—	—	—	—	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

$3.0B

$3.1B

$2.9B

$2.8B

$2.1B

$1.8B

$1.7B

$1.6B

$1.5B

$1.4B

—

$2.0B

$1.9B

$1.8B

$1.7B

—

$1.1B

$999M

$1.1B

$1.2B

$768M

$606M

$545M

$513M

$501M

$456M

Gross Margin

35.2%

35.9%

34.5%

38.3%

39.4%

41.5%

35.8%

32.9%

31.8%

32.1%

33.2%

32.6%

—

$394M

$339M

$353M

$317M

$363M

—

Research & Development

—

$74M

$69M

$68M

$59M

$53M

$47M

$39M

$40M

$39M

$37M

$34M

Depreciation

—

$109M

$103M

$104M

$97M

$91M

$90M

Total Operating Expenses

—

$519M

$429M

$453M

$402M

$424M

—

$590M

$585M

$570M

$676M

$734M

$752M

$407M

$297M

$240M

$226M

$197M

$129M

EBIT

$590M

$585M

$570M

$676M

$734M

$752M

$407M

$297M

$240M

$226M

$197M

$129M

EBITDA

$590M

$585M

$570M

$676M

$734M

$752M

$517M

$400M

$351M

$326M

$288M

$219M

Operating Margin

19.5%

19.0%

19.7%

22.9%

25.4%

26.6%

18.9%

16.1%

14.0%

14.1%

12.9%

9.2%

EBITDA Margin

19.6%

19.0%

19.7%

22.9%

25.4%

26.6%

24.1%

21.7%

20.5%

20.4%

19.1%

15.6%

—

$9M

$8M

$9M

$8M

$14M

—

$601M

$586M

$698M

$680M

$749M

—

Income Tax Expense

—

$122M

$108M

$122M

$115M

$107M

$73M

$59M

$41M

$81M

$54M

$26M

$498M

$494M

$493M

$593M

$586M

$662M

$346M

$242M

$207M

$151M

$144M

$96M

Net Margin

16.4%

16.1%

17.0%

20.1%

20.3%

23.4%

16.1%

13.1%

12.0%

9.4%

9.5%

6.8%

$6.83

$6.75

$7.98

$7.87

$8.89

$4.68

$3.27

$2.80

$2.04

$1.96

$1.33

Diluted EPS

$6.83

$6.79

$6.69

$7.88

$7.73

$8.67

$4.68

$3.27

$2.80

$2.04

$1.96

$1.33

Weighted Avg Basic

—

72M

73M

74M

—

Weighted Avg Diluted

—

73M

74M

75M

76M

—

WEST PHARMACEUTICAL SERVICES INC (WST) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does WEST PHARMACEUTICAL SERVICES INC Do?

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania. WEST PHARMACEUTICAL SERVICES INC (WST) is classified as a large-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Eric M. Green and employs approximately 10,700 people, headquartered in Exton, Pennsylvania. With a market capitalization of $18.2B, WST is one of the prominent companies in the Healthcare sector.

WEST PHARMACEUTICAL SERVICES INC (WST) Stock Rating — Hold (April 2026)

As of April 2026, WEST PHARMACEUTICAL SERVICES INC receives a Hold rating with a composite score of 44.9/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.WST ranks #734 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, WEST PHARMACEUTICAL SERVICES INC ranks #50 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

WST Stock Price and 52-Week Range

WEST PHARMACEUTICAL SERVICES INC (WST) currently trades at $258.54. The 52-week high for WST is $322.34, which means the stock is currently trading -19.8% from its annual peak. The 52-week low is $187.43, putting the stock 37.9% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is WST Overvalued or Undervalued? — Valuation Analysis

WEST PHARMACEUTICAL SERVICES INC (WST) carries a value factor score of 53/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 37.57x, compared to the Healthcare sector average of 23.63x — a premium of 59%. The price-to-book ratio stands at 5.89x, versus the sector average of 2.75x. The price-to-sales ratio is 6.20x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, WST trades at 32.05x EV/EBITDA, versus 6.34x for the sector.

Overall, WST's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

WEST PHARMACEUTICAL SERVICES INC Profitability — ROE, Margins, and Quality Score

WEST PHARMACEUTICAL SERVICES INC (WST) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 15.7%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 11.7% versus the sector average of -33.1%.

On a margin basis, WEST PHARMACEUTICAL SERVICES INC reports gross margins of 35.2%, compared to 71.5% for the sector. The operating margin is 19.5% (sector: -66.1%). Net profit margin stands at 16.4%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 14.6% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

WST Debt, Balance Sheet, and Financial Health

WEST PHARMACEUTICAL SERVICES INC has a debt-to-equity ratio of 6.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 3.02x, indicating strong short-term liquidity. Total debt on the balance sheet is $203M. Cash and equivalents stand at $629M.

WST has a beta of 0.73, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for WEST PHARMACEUTICAL SERVICES INC is 67/100, reflecting average volatility within the normal range for its sector.

WEST PHARMACEUTICAL SERVICES INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, WEST PHARMACEUTICAL SERVICES INC reported revenue of $3.02B and earnings per share (EPS) of $6.83. Net income for the quarter was $498M. Gross margin was 35.2%. Operating income came in at $590M.

In FY 2025, WEST PHARMACEUTICAL SERVICES INC reported revenue of $3.07B and earnings per share (EPS) of $6.83. Net income for the quarter was $494M. Gross margin was 35.9%. Revenue grew 6.3% year-over-year compared to FY 2024. Operating income came in at $585M.

In Q3 2025, WEST PHARMACEUTICAL SERVICES INC reported revenue of $805M and earnings per share (EPS) of $1.94. Net income for the quarter was $140M. Gross margin was 36.6%. Revenue grew 7.7% year-over-year compared to Q3 2024. Operating income came in at $168M.

In Q2 2025, WEST PHARMACEUTICAL SERVICES INC reported revenue of $767M and earnings per share (EPS) of $1.82. Net income for the quarter was $132M. Gross margin was 35.7%. Revenue grew 9.2% year-over-year compared to Q2 2024. Operating income came in at $154M.

Over the past 8 quarters, WEST PHARMACEUTICAL SERVICES INC has demonstrated a growth trajectory, with revenue expanding from $702M to $3.02B. Investors analyzing WST stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

WST Dividend Yield and Income Analysis

WEST PHARMACEUTICAL SERVICES INC (WST) currently pays a dividend yield of 0.3%. At this yield, a $10,000 investment in WST stock would generate approximately $$32.00 in annual dividend income. With a net margin of 16.4%, the dividend appears well-covered by earnings, suggesting sustainable payouts going forward.

WST Momentum and Technical Analysis Profile

WEST PHARMACEUTICAL SERVICES INC (WST) has a momentum factor score of 42/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 27/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 22/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

WST vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, WEST PHARMACEUTICAL SERVICES INC (WST) ranks #50 out of 838 stocks based on the Blank Capital composite score. This places WST in the top decile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing WST against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full WST vs S&P 500 (SPY) comparison to assess how WEST PHARMACEUTICAL SERVICES INC stacks up against the broader market across all factor dimensions.

WST Next Earnings Date

No upcoming earnings date has been announced for WEST PHARMACEUTICAL SERVICES INC (WST) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy WST? — Investment Thesis Summary

WEST PHARMACEUTICAL SERVICES INC presents a balanced picture with arguments on both sides. Low volatility (stability score 67/100) reduces downside risk.

In summary, WEST PHARMACEUTICAL SERVICES INC (WST) earns a Hold rating with a composite score of 44.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on WST stock.

Related Resources for WST Investors

Explore more research and tools: WST vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare WST head-to-head with peers: WST vs AZN, WST vs SLGL, WST vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

WST Expands Dublin Facility to Boost Injectable Therapy Capacity

ALGN vs. WST: Which Stock Should Value Investors Buy Now?

Down 30% This Year: Analysts Say These 2 Beaten-Down Stocks Are Poised to Rebound

Dublin Automation Expansion Could Be A Game Changer For West Pharmaceutical Services' Contract Platform (WST)

Does Dublin Automation Expansion Reshape the Bull Case for West Pharmaceutical Services’ Injectable Platform (WST)?

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks

WEST PHARMACEUTICAL SERVICES INC (WST) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does WEST PHARMACEUTICAL SERVICES INC Do?

WEST PHARMACEUTICAL SERVICES INC (WST) Stock Rating — Hold (April 2026)

WST Stock Price and 52-Week Range

Is WST Overvalued or Undervalued? — Valuation Analysis

WEST PHARMACEUTICAL SERVICES INC Profitability — ROE, Margins, and Quality Score

WST Debt, Balance Sheet, and Financial Health

WEST PHARMACEUTICAL SERVICES INC Revenue and Earnings History — Quarterly Trend

WST Dividend Yield and Income Analysis

WST Momentum and Technical Analysis Profile

WST vs Competitors — Healthcare Sector Ranking and Peer Comparison

WST Next Earnings Date

Should You Buy WST? — Investment Thesis Summary

Related Resources for WST Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

WST Expands Dublin Facility to Boost Injectable Therapy Capacity

ALGN vs. WST: Which Stock Should Value Investors Buy Now?

Down 30% This Year: Analysts Say These 2 Beaten-Down Stocks Are Poised to Rebound

Dublin Automation Expansion Could Be A Game Changer For West Pharmaceutical Services' Contract Platform (WST)

Does Dublin Automation Expansion Reshape the Bull Case for West Pharmaceutical Services’ Injectable Platform (WST)?